ReviewFrontiers in oncology2026
The triad of nasopharyngeal carcinoma pathogenesis: host genetics, viral infection, and environmental exposures.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory-Hematological Profiles in Nasopharyngeal Carcinoma and Suspicious Adenoid Hypertrophy: An Exploratory Single-Center Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) are geographically restricted malignancies, exhibiting significantly higher incidence in specific regions and among certain ethnic groups, indicating strong genetic and region-specific etiological influences. The pathogenesis of these malignancies illustrates a multifaceted interaction involving host genetic predisposition, viral infections, as well as various environmental and lifestyle factors. This mini review brings together existing evidence regarding the molecular genetic factors influencing both EBV and HR-HPV-associated NPC, focusing on gene polymorphisms, viral biomarkers, and risk modifiers that vary across populations. Recurrent genetic associations involved polymorphisms in GSTM1, CYP1A1, XRCC1, TNF, HLA microsatellites, and xenobiotic metabolism genes, particularly CYP2A6. Markers linked to EBV, including LMP1, EBNA1, and circulating plasma EBV DNA, exhibited a consistent association with NPC susceptibility. Similarly, HR-HPV markers including E6 and E7 oncoproteins, p16INK4a overexpression, and HPV DNA detection serve as critical biomarkers for HPV-driven HNCs, but categorically these associations haven't yet been discovered in regard to NPC. These findings classify NPC as a genetically modified, virus-related cancer and highlight the necessity for population-specific genetic risk assessment, EBV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.